Please try another search
For the three months ended 31 January 2018, CanniMed Therapeutics Inc revenues increased 41% to C$4.8M. Net income totaled C$5.3M vs. loss of C$3.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects (Gain) loss on derivative instruments decrease from C$2.4M (expense) to C$23.6M (income), Unrealized gain from changes in fair val increase of 60% to C$3.7M
Period Ending: | Jan 31, 2018 | Oct 31, 2017 | Jul 31, 2017 | Apr 30, 2017 |
---|---|---|---|---|
Total Revenue | 4.82 | 4.82 | 4.77 | 3.69 |
Gross Profit | 0.51 | -1.56 | 1.19 | 0.68 |
Operating Income | 8.34 | 0.33 | -1.07 | -1.66 |
Net Income | 5.32 | 0.59 | -1.36 | -1.85 |
Period Ending: | Jan 31, 2018 | Oct 31, 2017 | Jul 31, 2017 | Apr 30, 2017 |
---|---|---|---|---|
Total Assets | 124.25 | 106.15 | 107.66 | 112.15 |
Total Liabilities | 26.08 | 16.98 | 16.83 | 20.39 |
Total Equity | 98.18 | 89.17 | 90.83 | 91.76 |
Period Ending: | Jan 31, 2018 | Oct 31, 2017 | Jul 31, 2017 | Apr 30, 2017 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -5.88 | -2.71 | -2.43 | -2.03 |
Cash From Investing Activities | -1.72 | -6.63 | -1.65 | -1.02 |
Cash From Financing Activities | 1.54 | 55.72 | 56.27 | 60.09 |
Net Change in Cash | -6.06 | 46.38 | 52.19 | 57.04 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review